Brief: Anixa Biosciences Reports Updated Positive Survival Observations From Ongoing Phase 1 Trial Of Lira-Cel Ovarian Cancer CAR-T Therapy
11/05/2026 14:19
May 11 (Reuters) - Anixa Biosciences Inc ANIX.O: ANIXA BIOSCIENCES REPORTS UPDATED POSITIVE SURVIVAL OBSERVATIONS FROM ONGOING PHASE 1 TRIAL OF LIRA-CEL OVARIAN CANCER CAR-T THERAPY ANIXA BIOSCIENCES INC - NO DOSE-LIMITING TOXICITIES, ICANS, OR SIGNIFICANT CRS OBSERVED IN FIRST THREE DOSE COHORTS Source text: ID:nPn7wHD3Ba Further company coverage: ANIX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Anixa Biosciences
See all newsBrief: Anixa Biosciences Announces First Case Of Stable Disease For Three Months In Ovarian Cancer Car-T Clinical Trial
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
Anixa Biosciences Inc reports results for the quarter ended July 31 - Earnings Summary
Anixa Biosciences Inc expected to post a loss of 9 cents a share - Earnings Preview
Factbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine